XOMA Royalty Corporation (XOMAP)

Healthcare · Pharmaceuticals · Price $24.98
Updated: Aug 25, 2026
Low Multiple — Healthcare
P/E of 15.91x is below the 18x moderate threshold Zyberno applies to Healthcare businesses — potentially a value opportunity.
P/E Ratio (TTM)
15.91x
Moderate P/E - fairly valued relative to market average
Earnings Yield
6.29%
1 / P/E Ratio
EPS (TTM)
$1.57
Diluted Earnings Per Share
Stock Price
$24.98
Current Market Price
PEG Ratio
-999.00
Negative growth - PEG not meaningful
Earnings Growth
-33.64%
Net Income Growth (Linear)

🧮 XOMAP P/E Ratio Calculation

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Stock Price $24.98
÷
Earnings Per Share (TTM) $1.57
= P/E Ratio 15.91x

What is the P/E Ratio?

The Price-to-Earnings (P/E) Ratio is one of the most widely used valuation metrics. It tells you how much investors are willing to pay for each dollar of a company's earnings. Zyberno calculates P/E using trailing twelve month (TTM) diluted earnings from official SEC filings.

P/E Ratio = Stock Price ÷ Earnings Per Share (TTM)
Using diluted EPS which accounts for stock options and convertible securities

How to Interpret the P/E Ratio

Low P/E (Under 15x)

May indicate undervaluation, or the market expects declining earnings. Common in mature, slow-growth industries.

Average P/E (15-20x)

Roughly in line with historical S&P 500 average. Suggests fairly valued with moderate growth expectations.

High P/E (20-35x)

Investors expect above-average earnings growth. Common for technology companies and market leaders.

Very High P/E (35x+)

Extreme growth expectations priced in. Significant valuation risk if growth slows.

PEG Ratio: P/E Adjusted for Growth

The PEG Ratio addresses a key limitation of P/E by factoring in earnings growth. A PEG of 1.0 suggests fair value; below 1.0 may indicate undervaluation, while above 2.0 suggests a premium price for growth.

PEG Ratio = P/E Ratio ÷ Earnings Growth Rate
XOMAP: 15.91x ÷ -33.64% = -999.00

P/E Ratio Limitations

The P/E ratio doesn't work for companies with negative earnings. It can be manipulated by one-time charges or gains, and it doesn't account for debt levels or growth rates. Use P/E alongside PEG ratio, EV/EBITDA, and Owner Earnings yield for a complete picture.

Comparing Valuation Metrics

EPS: $1.57 →

The denominator in the P/E calculation. Represents profit allocated to each outstanding share.

Price-to-Book: N/A

Compares stock price to book value. Useful for asset-heavy industries like banking and manufacturing.

EV/EBITDA: N/A

Accounts for debt and is useful for comparing companies with different capital structures.

Owner Earnings Yield →

Warren Buffett's preferred metric. Shows cash return to owners as a percentage of market cap.

📊 Full XOMAP Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

📈 XOMAP Earnings Per Share

Deep dive into EPS trends, quarterly history, and earnings growth analysis.

🏆 XOMAP ROIC

Measure capital efficiency — how well management deploys every dollar invested.

💎 XOMAP Intrinsic Value

Calculate what XOMAP is truly worth using DCF and Owner Earnings models.

💵 XOMAP Owner Earnings

Warren Buffett's preferred measure of true earning power and cash generation.

🛡️ XOMAP Margin of Safety

See if XOMAP is trading below its intrinsic value.

View Full XOMAP Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

Summary: XOMAP P/E Ratio

XOMA Royalty Corporation (XOMAP) trades at a P/E of 15.91x, which Zyberno classifies as a low multiple for a Healthcare company — below the 18x level Zyberno considers moderate for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 6.29%. May indicate a value opportunity or reflect market concerns about future earnings.

Based on 0 quarters of SEC filings, XOMAP's EPS is currently $1.57 on a trailing twelve-month basis. Zyberno cross-references the P/E ratio with business quality — a high multiple on a high-quality business (strong ROE, ROIC, and FCF) carries less risk than the same multiple on a weaker business. For complete financial analysis, view the full XOMAP stock report on Zyberno.

Frequently Asked Questions

What is XOMAP's current P/E Ratio?

XOMA Royalty Corporation's trailing twelve month (TTM) P/E Ratio is 15.91x, within the context of Healthcare sector multiples where Zyberno considers 18–28x moderate. Investors are paying $15.91 for every $1 of annual earnings.

Is XOMAP's P/E Ratio high or low?

XOMA Royalty Corporation (XOMAP) trades at a P/E of 15.91x, which Zyberno classifies as a low multiple for a Healthcare company — below the 18x level Zyberno considers moderate for healthcare companies where pipeline value and patent protection justify premium multiples. Earnings yield: 6.29%. May indicate a value opportunity or reflect market concerns about future earnings.

What is XOMAP's earnings yield?

XOMAP's earnings yield is 6.29%, which is the inverse of the P/E ratio (1 ÷ P/E). This represents the theoretical return if all earnings were distributed to shareholders.

How is P/E Ratio calculated?

P/E Ratio = Stock Price ÷ EPS. For XOMAP: $24.98 ÷ $1.57 = 15.91x.

What is XOMAP's PEG Ratio?

XOMAP's PEG Ratio is -999.00. Negative growth - PEG not meaningful. PEG below 1.0 is often considered undervalued, while above 2.0 may indicate overvaluation relative to growth.

📊 Full XOMAP Stock Report

See XOMAP's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 XOMAP ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

📈 XOMAP ROE

Compare to Return on Equity and understand the impact of leverage on returns.

🎯 XOMAP Earnings Surprise (SUE)

See whether XOMAP is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 XOMAP Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 XOMAP Net Income

See the bottom-line profit that drives return calculations.

📊 XOMAP EPS

Earnings per share — net income on a per-share basis.

View Full XOMAP Report Find More Quality Stocks
Scroll to Top